Nouveau Visage NEWDERM 5-in-1 Regenerative Microneedling System
Nouveau Visage, a French biomedical aesthetics brand announces the UK launch of a new regenerative microneedling system designed for medical aesthetic clinics and dermatology practices. The brand enters the UK market in partnership with Fox Pharma, MedFx and John Bannon.
Developed by Laboratoire Nouveau Visage, the system is built around Regen³ Complex, a patented, proprietary technology combining exosomes, PDRN and biomimetic peptides within a single stable microneedling formulation. Designed to activate multiple regenerative pathways simultaneously, the complex supports cellular communication, fibroblast stimulation and extracellular matrix renewal, positioning the brand within the fast-growing regenerative aesthetics category.
The Nouveau Visage portfolio has been developed primarily for medical aesthetic practitioners delivering advanced microneedling treatments. The professional treatment range, known as NEWDERM, is built around the pillar of ‘one indication, one solution’ - with five targeted protocols addressing key target concerns including:
NEWDERM Age Control, designed to address wrinkles, dehydration and loss of elasticity through deep hydration and stimulation of dermal regeneration
NEWDERM Bright, formulated to target melasma, sun damage and uneven skin tone by limiting melanin synthesis while supporting skin barrier recovery
NEWDERM Eye, developed specifically for the delicate periorbital area to improve dark circles, under eye bags and fine lines while strengthening skin elasticity
NEWDERM Hair, a regenerative scalp treatment designed to support follicle health, improve hair density and revitalise the scalp
NEWDERM Lift, focused on improving skin laxity and dermal structure through collagen stimulation and strengthening of the dermal matrix
All protocols utilise the Regen³ Complex, which combines more than 100 billion exosomes per vial (the highest known concentration) with PDRN and biomimetic peptides. These components work through complementary regenerative pathways to support tissue repair, collagen synthesis and improved skin structure, delivering visible improvements in elasticity, firmness and radiance over a structured course of treatment. By actively stimulating the skin’s natural repair and regeneration pathways, the Regen³ Complex enhances the effectiveness of every formulation, ensuring faster, more visible, and longer-lasting results.
Carlos Royo, Executive Partner & CEO at Nouveau Visage commented: "The UK aesthetics market continues to move rapidly towards regenerative and biologically-driven treatments, and Nouveau Visage represents a significant step forward within this space, offering an innovative and versatile treatment portfolio for discerning clinics. We are excited to be launching in the UK and adding this market to our growing list of territories – and we look forward to working closely with aesthetic practitioners, clinics and pharmacy partners to support this exciting rollout."
Dr Apostolos Vlachogiorgos, plastic surgeon and early UK adopter, added: "Regenerative aesthetics is increasingly focused on how we stimulate the skin’s own repair mechanisms rather than simply replacing volume or masking signs of ageing. What makes Nouveau Visage particularly interesting from a clinical perspective is the way the Regen³ Complex combines three complementary regenerative technologies within one formulation. In practice, this allows practitioners to achieve improvements in skin texture, elasticity and radiance through a structured treatment course that is both clinically grounded and easy to incorporate into existing microneedling protocols."
Clinics interested in learning more about the Nouveau Visage system can contact Fox Pharma via contact@nouveau-visage.com.
